Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
BLRX
#4858
BioLineRX Ltd
2.380
0
USD
+2.59%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+2.59%
Monthly Change
-7.03%
6 month change
-15.30%
Year Change
-15.30%
Previous Close
2.320
0
Open
2.380
0
Bid
Ask
Low
2.380
0
High
2.380
0
Volume
1
Markets
US Stock Market
Healthcare
BLRX
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2020
2021
2022
2023
2024
2025
TTM
Cash from operating activities
23.21 M
23.57 M
26.24 M
22.61 M
43.87 M
8.07 M
—
Cash from investing activities
16.67 M
38.22 M
4.01 M
1.44 M
29.37 M
8.54 M
—
Cash from financing activities
17.87 M
57.75 M
20.44 M
15.06 M
20.66 M
8.88 M
—
Free cash flow
23.21 M
23.57 M
26.24 M
22.61 M
43.87 M
8.07 M
—
BioLineRx Ltd - American Depositary Shares
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
News
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss
BioLineRx shares rise over 7% on better-than-expected earnings
BioLineRx stock rises after partner receives key patent allowance
Hemispherian receives patent allowance for cancer drug GLIX1
BioLineRx stock rises after securing key patent for cancer treatment
BioLineRx receives key patent for cancer treatment GLIX1
BioLineRx Ltd. (BLRX) Investor Call Transcript
BioLineRx and Hemispherian form joint venture to develop brain cancer drug
BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript
BioLineRx stock maintains buy rating at H.C. Wainwright on cancer data